##  Genomics England Limited

## Board Meeting

## Action Points from Meeting held on 16 July 2019

|  |  |  |  |
| --- | --- | --- | --- |
| **ACTION** | **OWNER** | **DATE** | **STATUS** |
| Discuss the need to expedite Whitechapel with David Williams in DHSC and report back. | SO | July | New |
| GC to fix a date for a discussion of access to data. | GC | July | New |
| Define core principles for developing NGIS. | NM | July | New |

## Genomics England Limited –Board Meeting

## Minutes of Meeting held on 16 July 2019

|  |  |
| --- | --- |
| Present:  | Jon Symonds (JS) (Chair) |
|  | Prof Mark Caulfield (MC) (Interim CEO) |
|  | Gary Cook (GC) |
|  | Prof Dame Sally Davies (SD) |
|  | Prof Dame Kay Davies (KD) |
|  | Sir Ron Kerr (RK) |
|  | Steve Oldfield (SO) |
|  | Lord David Prior (DP) |
|  | Prof Keith Stewart (KS) |
|  | Nick Maltby (NM) |
|  |  |
| In attendance: | Mark Bale (MB) |
|  | Graham Colbert (GXC) |
|  | Tom Fowler (TF) |
|  | John Hatwell (JH) |
|  | Fiona Maleady-Crowe (FMC) |
|  |  |

**19-20/014 – Apologies:** Prof Sir John Bell, Prof Ewan Birney, Kristen McLeod, Prof Michael Parker.

**19-20/015– Chair’s Introduction:**

* JS welcomed the directors to the meeting. JS noted that the meeting was quorate.
* JS advised the Board that the new CEO appointment has been delayed.
* JS thanked MC on behalf of the Board for his work as interim CEO during the transition period.
* [CONFIDENTIAL ITEM] JS informed the Board that he is to be appointed Chair of GSK. The compliance process is going through Cabinet Office with a view to there being a consistent process between GeL and GSK.

**19-20/016– Declarations of Conflicts of Interest:**

* JS reminded the Board that all conflicts needed to be declared.

**19-20/017– Approval of the Minutes of the May Board Meeting and Actions Arising:**

The minutes of the May Board Meeting were approved. NM was authorised sign the minutes as a true record of the meeting. The actions arising and outstanding were as follows:

|  |  |  |  |
| --- | --- | --- | --- |
| **ACTION** | **OWNER** | **DATE** | **STATUS** |
| Circulate a note to the Board on the budget outcome together with the strategic financial parameters for the CSR once finalised. | NM | March | Discussions are ongoing.  |
| GeL with NHSE to produce a clear, risk adjusted timeline for the delivery of NGIS including high level timeline to deliver MVP 1.0 and MVP 2.0. | PC/SH | March | Outstanding.  |
| Share new-borns document with the Board. | MC | May | In progress |
| Circulate national sequencing strategy when ready.  | MC | May | Done |

**19-20/016 Interim Chief Executive’s Report (MC)**

* *Diagnostic yield*: MC showed the Board a slide on diagnostic yield. MC will ensure that yield is presented in this way in the future.
* *GMS/NGIS*: we continue to work to bring the GMS for WGS live. NGIS will now enter beta in August when safe and seek to go live end October/November. NHSD is conducting a review and will also consider the plan to NGIS 1.0 and 2.0 as part of the review.
* *Genomic volunteers*: the genomics volunteers program will not be done with the NHS. It may now continue as part of the ADD cohort. Funding for the 5m remains be determined.
* *Data release*: there will be a new data release this week. We will have 1.6/1.7bn data points.
* *National sequencing strategy*: MC confirmed that the sequencing market is at least 18 months to 2 years away from having another deployable sequencing technology.
* *International development*: it was queried whether it might be possible to call on the international aid budget for some of the international partnerships GeL is looking at.
* *Funding/5m*: MC updated the Board on submissions for the CSR and funding for the 5m.
* *Patient Choice*: [FMC and TF joined the meeting]. FMC and TF updated the Board on the work that has been undertaken around patient choice for the GMS. We will continue to iterate the patient choice documents. The Board congratulated FMC and TF on the patient choice work.

**19-20/017 CFO/COO’s Report (GXC)**

* GXC took the Board through his reports.
* *Accounts:* Deloitte will sign the accounts off by next Friday. If members of the Board have any comments they should send them through to GXC. It was noted that the Audit Committee recommend approval to Board. **The Board delegated authority to sign off the accounts to JS and MC as long as there were no material change**.
* *Reporting pipeline*: GXC confirmed we will finish analysing the tail in early August. We have also finally finished the pilot programme. It was confirmed that there will be little activity at the sequencing centre in the remaining months of the year although we expect there to be some samples funded by the life sciences strategy.
* *19/20 Budget*: this remains to be resolved. GC is assisting. Other ALBs are yet to agree budgets.
* *Storage and compute*: the new Weka has now been installed. It has achieved good benchmarking scores.
* *NGIS*: see above.
* *People:* GXC noted that a proposal regarding the future Target Operating Model was approved by the audit committee on 15 July.
* *Accommodation*: There was a discussion of the situation around new accommodation including the Whitechapel option

**19-20/018 Committee Reports**

* There was no discussion of committee reports.

**19-20/020 Actioning feedback from Board Away Day (JS/JH)**

* JS will take points from the Away Day and build them into future agendas. It was agreed that it had been a useful event.

**19-20/021– Feedback from Partnership Board Report (JS):**

* See above.

**19-20/022 – [CONFIDENTIAL ITEM] Sequencing strategy (JS):**

* There was a discussion of what should be the Company’s approach to procuring whole genome sequencing over the next 5 years

**19-20/023- [CONFIDENTIAL ITEM]**

**19-20/024- Any Other Business:** there was no other business.

**19-20/025-** Date, Time and Agenda for Next Meeting: IT WAS NOTED that the next Board meeting would be held on **Monday 30 September 2019** between 14.00 – 17.00 at Genomics England at Carthusian Street.

**Close: The meeting closed at 1620**.

…………………………………………………. ……………………………………………………..

Signed Dated